Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems.


Journal

Drugs & therapy perspectives : for rational drug selection and use
ISSN: 1172-0360
Titre abrégé: Drugs Ther Perspect
Pays: New Zealand
ID NLM: 9308798

Informations de publication

Date de publication:
2021
Historique:
accepted: 11 07 2021
pubmed: 10 8 2021
medline: 10 8 2021
entrez: 9 8 2021
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new species of β-coronavirus genus named severe acute respiratory syndrome coronavirus 2. The COVID-19 pandemic, which started in late 2019 and continues as at mid-2021, has caused enormous damage to health and lives globally. The urgent public health need has led to the development of vaccines against COVID-19 in record-breaking time. The COVID-19 vaccines have been widely rolled out for the masses by many countries following approval for emergency use by the World Health Organization and regulatory agencies in many countries. In addition, several COVID-19 vaccine candidates are undergoing clinical trials. However, myths, fears, rumors, and misconceptions persist, particularly in regard to adverse events. In this commentary, we describe the adverse events associated with COVID-19 vaccines and discuss why it is essential to have a functional adverse event monitoring system in this context.

Identifiants

pubmed: 34366660
doi: 10.1007/s40267-021-00852-z
pii: 852
pmc: PMC8327058
doi:

Types de publication

Journal Article

Langues

eng

Pagination

376-382

Informations de copyright

© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021.

Déclaration de conflit d'intérêts

Conflict of interestSunil Shrestha (SSa), Januka Khatri (JK), Sujyoti Shakya (SSb), Krisha Danekhu (KD), Asmita Priyadarshini Khatiwada (APK), Ranjit Sah (RS), Bhuvan KC (BKC), Vibhu Paudyal (VP), Saval Khanal (SK), and Alfonso J. Rodriguez-Morales (AJM) have no conflicts of interest that are directly relevant to the content of this article.

Références

Pathogens. 2020 Jun 28;9(7):
pubmed: 32605194
Travel Med Infect Dis. 2020 Sep - Oct;37:101831
pubmed: 32750416
Expert Opin Drug Saf. 2020 Sep;19(9):1173-1191
pubmed: 32755492
MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):46-51
pubmed: 33444297
Public Health. 2021 Apr;193:57-60
pubmed: 33743214
J Microbiol Immunol Infect. 2021 Apr;54(2):159-163
pubmed: 32265180
Int J Equity Health. 2020 Jun 26;19(1):104
pubmed: 32586388
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Ann Clin Microbiol Antimicrob. 2020 Sep 2;19(1):40
pubmed: 32878641
Vacunas. 2021 May-Aug;22(2):93-97
pubmed: 33727904
Lancet. 2020 May 16;395(10236):e85-e86
pubmed: 32380043
BMJ. 2020 Dec 11;371:m4826
pubmed: 33310706
Bull World Health Organ. 2000;78(2):178-85
pubmed: 10743282
J Infect Dev Ctries. 2020 May 31;14(5):450-453
pubmed: 32525830
Ther Adv Drug Saf. 2020 Jun 12;11:2042098620922480
pubmed: 32587678
AAPS PharmSciTech. 2020 Aug 5;21(6):225
pubmed: 32761294
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Travel Med Infect Dis. 2020 Sep - Oct;37:101830
pubmed: 32755673
Vaccines (Basel). 2021 Apr 16;9(4):
pubmed: 33923530
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
J Am Geriatr Soc. 2020 May;68(5):926-929
pubmed: 32255507
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Travel Med Infect Dis. 2019 Jan - Feb;27:27-32
pubmed: 30550839
N Engl J Med. 2021 Jul 8;385(2):187-189
pubmed: 33951357
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Lancet Infect Dis. 2021 May;21(5):637-646
pubmed: 33485468
Travel Med Infect Dis. 2020 Mar - Apr;34:101623
pubmed: 32179124
J Community Health. 2021 Dec;46(6):1244-1251
pubmed: 33877534
Travel Med Infect Dis. 2021 Sep-Oct;43:102126
pubmed: 34144178
Lancet. 2020 Aug 15;396(10249):479-488
pubmed: 32702299
Lancet Infect Dis. 2021 Jan;21(1):39-51
pubmed: 33069281
Lancet. 2021 Feb 20;397(10275):671-681
pubmed: 33545094
Lancet. 2020 Sep 26;396(10255):887-897
pubmed: 32896291
Travel Med Infect Dis. 2021 Mar-Apr;40:101989
pubmed: 33578045
Clin Case Rep. 2020 Dec 08;9(2):747-750
pubmed: 33598238
Indian J Clin Biochem. 2021 Oct;36(4):427-439
pubmed: 33814753
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
Lancet Infect Dis. 2021 Feb;21(2):181-192
pubmed: 33217362
High Throughput. 2018 Nov 23;7(4):
pubmed: 30477159

Auteurs

Sunil Shrestha (S)

School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 47500 Bandar Sunway, Selangor Malaysia.

Januka Khatri (J)

Department of Pharmacy, School of Science, Kathmandu University, Dhulikhel, Kavre Nepal.

Sujyoti Shakya (S)

Department of Pharmaceutical and Health Service Research, Nepal Health Research and Innovation Foundation, Lalitpur, Nepal.
Department of Pharmacy, Nobel College, Sinamangal, Kathmandu, Nepal.

Krisha Danekhu (K)

Department of Pharmaceutical and Health Service Research, Nepal Health Research and Innovation Foundation, Lalitpur, Nepal.

Asmita Priyadarshini Khatiwada (AP)

Department of Pharmaceutical and Health Service Research, Nepal Health Research and Innovation Foundation, Lalitpur, Nepal.

Ranjit Sah (R)

Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal.
National Public Health Laboratory, Kathmandu, Nepal.

Bhuvan Kc (B)

School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 47500 Bandar Sunway, Selangor Malaysia.

Vibhu Paudyal (V)

School of Pharmacy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.

Saval Khanal (S)

Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, United Kingdom.

Alfonso J Rodriguez-Morales (AJ)

Grupo de Investigación Biomedicina, Faculty of Medicine, Fundacion Universitaria Autonoma de Las Americas, Pereira, Risaralda Colombia.
School of Medicine, Universidad Privada Franz Tamayo (UNIFRANZ), Cochabamba, Bolivia.
Universidad Cientifica del Sur, Lima, Peru.

Classifications MeSH